apixaban / Generic mfg. - LARVOL DELTA

Medication Use Evaluation of Apixaban in a South Texas Academic Institution (ASHP 2025) - No abstract available

Clinical

Evaluation of Apixaban Dosing Appropriateness in Patients with Atrial Fibrillation (ASHP 2025) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular

Comparison of Activated Partial Thromboplastin Time (aPTT) Effect Between Two Four-Factor Prothrombin Complex Concentrate (4F-PCC) Formulations in Patients on Apixaban (ASHP 2025) - No abstract available

Clinical

Suspected Drug-Induced Drug Rash with Eosinophilia and Systemic Symptoms Syndrome: Allopurinol, Furosemide, and Apixaban as Potential Triggers (ASHP 2025) - No abstract available

Eosinophilia

Evaluation of the Safety and Efficacy of Different Apixaban Lead-In Dosing Regimens in the Management of Acute Venous Thromboembolism (ASHP 2025) - No abstract available

Clinical • Cardiovascular • Venous Thromboembolism

Evaluation of Apixaban in Hemodialysis Patients Compared to Non-Hemodialysis Patients (ASHP 2025) - No abstract available

Clinical • Renal Disease

Evaluation of Low-Dose 4-Factor Prothrombin Complex Concentrate for Reversal of Intracerebral Hemorrhages in Patients taking Apixaban or Rivaroxaban. (ASHP 2025) - No abstract available

Clinical • Cerebral Hemorrhage • Hematological Disorders

Outcomes with Full Versus Reduced Dose Rivaroxaban and Apixaban After Initial Venous Thromboembolism Treatment (ASHP 2025) - No abstract available

Cardiovascular • Venous Thromboembolism

Efficacy and Safety of Fixed Versus Weight-Based Factor Eight Inhibitor Bypassing Activity (FEIBA) for Apixaban or Rivaroxaban Associated Intracranial Hemorrhage (ASHP 2025) - No abstract available

Clinical • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders

Evaluating prescribing practices of rivaroxaban and apixaban for the treatment of venous thromboembolism among patients with renal dysfunction (ASHP 2025) - No abstract available

Clinical • Cardiovascular • Nephrology • Renal Disease • Venous Thromboembolism

Efficacy and Safety of Reduced Apixaban and Rivaroxaban Oral Lead-In Dosing After Receipt of Parenteral Anticoagulation: A Literature Review (ASHP 2025) - No abstract available

Clinical • Review

Bleeding Rates of Apixaban versus Unfractionated Heparin in ICU Patients with Acute Kidney Injury (ASHP 2025) - No abstract available

Clinical • Acute Kidney Injury • Nephrology • Renal Disease

Medication Use Evaluation of Rivaroxaban and Apixaban in Patients with Obesity in an Urban Academic Medical Center (ASHP 2025) - No abstract available

Clinical • Genetic Disorders • Obesity

Medication Use Evaluation of Apixaban dosing and indication in a small community hospital (ASHP 2025) - No abstract available

Clinical

An Inpatient Retrospective Evaluation of apixaban and rivaroxaban Loading Dose Strategies in the Setting of Acute Venous Thromboembolism (ASHP 2025) - No abstract available

Retrospective data • Cardiovascular • Venous Thromboembolism

Incidence of Stroke and VTE with Off-Label Dose Reduction of Apixaban for Atrial Fibrillation (ASHP 2025) - No abstract available

Atrial Fibrillation • Cardiovascular

Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial. (PubMed, BMJ Open) - P4 | "Oral factor Xa inhibitors (oral FXaI, eg, apixaban, edoxaban or rivaroxaban) are commonly prescribed for this indication. The trial is registered at clinicaltrials.gov with the identifier NCT06650501. NCT0665050."

Clinical protocol • Journal • Atrial Fibrillation • Cardiovascular • Infectious Disease • Venous Thromboembolism

Thyrotoxicosis-Induced Chordal Rupture Causing Severe Mitral Regurgitation: Surgical Management and Outpatient Recovery. (PubMed, JACC Case Rep) - "Thyrotoxicosis can cause chordal rupture and flail leaflet. Repair is preferred, but replacement is appropriate when repair is not durable. Management requires endocrine-cardiac coordination and individualized antithrombotic therapy. Expect early ejection-fraction decline after surgical correction."

Journal • Atrial Fibrillation • Cardiovascular • Endocrine Cancer • Heart Failure

Optimizing PNH treatment with the complement inhibitor pegcetacoplan: A case report (ASH 2025) - "The current treatment landscape includes 6 approved complement cascade inhibitors: 3 C5 inhibitors (eculizumab, ravulizumab, crovalimab), 1 C3/C3b inhibitor (pegcetacoplan), 1 factor B inhibitor (iptacopan), and 1 factor D inhibitor used as add-on treatment (danicopan)...Concomitant medications included apixaban, penicillin, and folic acid. In November 2020, her platelets count declined, and a bone marrow evaluation was diagnostic for moderate aplastic anemia (55-65% cellularity for age) and she was started on eltrombopag and cyclosporin. Despite ravulizumab and eltrombopag treatments, the patient developed significant anemia related to extravascular hemolysis (hemoglobin, 5.7 g/dL; LDH, 495 U/L; C5, 26.1 mg/dL [high]; complement hemolytic activity 50 [CH50], 7 U/mL [low])...After receiving both pegcetacoplan and iptacopan for 1 week and rivaroxaban 10 mg once daily for 48 hours, pegcetacoplan treatment ended on May 16, 2024... For this patient with PNH, the..."

Case report • Clinical • Anorexia • Aplastic Anemia • Complement-mediated Rare Disorders • Hematological Disorders • Infectious Disease • Meningococcal Infections • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases

Efficacy and safety of low-dose vs. standard-dose direct oral anticoagulants for secondary prevention of cancer associated thrombosis: A systematic review and meta-analysis (ASH 2025) - " We performed a meta-analysis of randomized controlled trials (RCTs) and retrospective and prospective observational studies evaluating reduced-dose apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily), compared with standard-dose (5 mg twice daily for apixaban, 20 mg once daily for rivaroxaban) for the extended treatment of VTE. Extended-duration anticoagulation with reduced-dose DOACs in patients with active cancer demonstrated non-inferior efficacy for preventing recurrent VTE compared to full-dose regimens, with no significant differences in all-cause mortality, major bleeding, or clinically relevant non-major bleeding. In a randomized trial subgroup analysis, reduced-dose DOACs were associated with a lower risk of composite bleeding. These findings support the consideration of reduced-dose DOACs as a safer alternative for long-term anticoagulation in cancer patients."

Retrospective data • Review • Oncology • Thrombosis • Venous Thromboembolism

Real-world comparative bleeding outcomes of direct oral anticoagulants versus warfarin in adults: Insights from observational evidence (ASH 2025) - "Background: Direct oral anticoagulants (DOACs) – apixaban, rivaroxaban, dabigatran, and edoxaban– are increasingly preferred over warfarin for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. This review provides robust real-world evidence that DOACs offer a superior safety and effectiveness profile compared to warfarin in adult patients requiring anticoagulation. DOACs significantly reduce the incidence of ICH and stroke– two of the most clinically devasting complications– while maintaining comparable or lower rates of major and GI bleeding. These findings validate guideline recommendations and strongly support the preferential use of DOACs as the standard of care for anticoagulation in everyday clinical practice."

Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Cerebral Hemorrhage • CNS Disorders • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Venous Thromboembolism

Delayed pulmonary embolism following oocyte retrieval in invitro fertilization: A neglected risk factor for thromboembolic events? (ASH 2025) - "Treatment: The patient was managed with intravenous heparin with a subsequent transition to apixaban after stabilization. This case highlights the diagnostic dilemma and management of delayed PE in ART patients. It emphasizes the importance of early recognition and the need for a high index of suspicion for PE, even in the absence of classic risk factors. Prophylactic anticoagulation may be beneficial in ART patients who are at high risk to prevent thromboembolic events, particularly in those with additional risk factors."

Preclinical • Cardiovascular • Genetic Disorders • Gynecology • Hematological Disorders • Obesity • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Venous Thromboembolism

Navigating triple therapy in a high-risk cardiac patient with a covered stent and embolic stroke: A case report (ASH 2025) - "He was diagnosed with NSTEMI, and was initiated on aspirin, clopidogrel, enoxaparin, and nitroglycerin...Persistent cardiogenic shock necessitated Impella CP support, vasopressors (epinephrine, norepinephrine), and inotropes (dobutamine)...Following readmission, neurological evaluation revealed small subacute infarcts, following which anticoagulation with enoxaparin (later apixaban) was initiated alongside DAPT (aspirin, clopidogrel)...Repeat coronary angiography plays a major role here, allowing physicians to assess stent integrity and to make informed decision about de-escalation or continuation of therapy. Unfortunately, there are no current guidelines specifically addressing management strategies for patients with coronary artery aneurysms and recent embolic stroke, underscoring an urgent need for further research in this area."

Case report • Clinical • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Depression • Heart Failure • Hematological Disorders • Ischemic stroke • Nephrology • Peripheral Arterial Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases • Thrombosis

Malignancy-associated internal jugular venous thrombosis following chemoradiation for oropharyngeal carcinoma (ASH 2025) - "Six months prior, he was diagnosed with HPV-positive (p16+) oropharyngeal SCC with nodal involvement, treated with carboplatin/fluorouracil chemotherapy and 14 days of radiation...Anticoagulation choice (apixaban) required careful consideration of renal function and bleeding risk (history of GI toxicity, anemia). This case underscores the heightened thrombotic risk in HNSCC patients due to the confluence of disease biology, aggressive local therapy, and patient-specific factors like CKD. Vigilance for atypical UEDVT presentations and individualized anticoagulation strategies are crucial in this complex population."

Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Head and Neck Cancer • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Oncology • Oropharyngeal Cancer • Renal Disease • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thrombosis • Venous Ulcer

Pulmonary vein thrombosis following bronchoscopic cryobiopsy: A case report (ASH 2025) - "His hemoptysis gradually resolved, and he was discharged on Apixaban... Pulmonary vein thrombosis is a rare but serious complication that may occur following bronchoscopic cryobiopsy. This case highlights the importance of recognizing this potential adverse outcome, especially in patients presenting with unexplained respiratory symptoms post-procedure. Early detection and anticoagulation are critical to managing this condition and preventing systemic embolization."

Case report • Clinical • Atrial Fibrillation • Cardiovascular • Cough • Diabetes • Fibrosis • Genetic Disorders • Hematological Malignancies • Hypertension • Immunology • Lymphoma • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Sarcoidosis • Sleep Disorder • Thrombosis